CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

NCT07053462 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

End-Stage Renal Disease
End Stage Renal Disease on Dialysis
End Stage Renal Disease With Renal Transplant
Kidney Transplant Rejection
Kidney Tumor
Kidney Failure
Kidney Ischemia

Interventions

BIOLOGICAL: Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney
PROCEDURE: Kidney Transplantation with Standard Care

Sponsor

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC